---
title: "Merck KGaA in Talks to Acquire U.S. Cancer Biotech Springworks, Reuters Says, Citing Sources"
date: "2025-02-10 23:42:00"
summary: "Germany's Merck KGaA is in advanced talks to buy U.S. cancer and rare diseases biotech company Springworks Therapeutics, Reuters says, citing unnamed sources.The deal could be finalized in the comings weeks, if the talks are successful, Reuters reports.Merck KGaA said in a statement that it would continuously assess options and..."
categories:
  - "Dow Jones Newswires"
lang:
  - "en"
translations:
  - "en"
tags:
  - "Dow Jones Newswires"
menu: ""
thumbnail: ""
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

* Germany's Merck KGaA is in advanced talks to buy U.S. cancer and rare diseases biotech company Springworks Therapeutics, Reuters says, citing unnamed sources.
* The deal could be finalized in the comings weeks, if the talks are successful, Reuters reports.
* Merck KGaA said in a statement that it would continuously assess options and would announce any transactions as and when they materialize, according to Reuters. Springworks declined to comment to Reuters.

Full story: https://bit.ly/40UCAR2

Write to Helena Smolak at helena.smolak@wsj.com

[Dow Jones Newswires](https://www.tradingview.com/news/DJN_DN20250210006971:0-merck-kgaa-in-talks-to-acquire-u-s-cancer-biotech-springworks-reuters-says-citing-sources/)
